Phoenix, March 26, 2018 --
Premier Biomedical Inc., (OTC: BIEI) ("the Company"), today reviewed recent accomplishments in interview on Uptick Newswire’s “Stock Day” podcast with Everett Jolly.
Premier Biomedical consists of two divisions, one focused on biologics and the other on topical pain relief products. The pain relief division is revenue-generating and has grown from one product a year ago, to five products today, distributed through the company’s website, www.painreliefmeds.com, and by a number of regional pharmacies and an on-line pharmacy, HealthWarehouse.com.
“Last time we spoke, you were delving into the process of sales for your many products,” said Jolly. “Also, you have been working diligently in becoming financially independent, can you expand on that?”
“We came out with five new pain relief products in 2017, and now have hired a national sales director and three sales managers. Additionally, we are working with retired NFL players, which has led to an expansion into a new line of enhanced Sports Strength pain relievers,” Hartman commented. “I think the progress we have made with the pain relief products is going to make us financially independent in this calendar year.”
To listen to the full interview please click here to the following link:
About Premier Biomedical Inc.
Premier Biomedical, Inc. has acquired exclusive licenses for patent-pending medications/medical procedures to develop extracorporeal treatments for a significant number of the most debilitating and often fatal illnesses affecting mankind: Amyotrophic Lateral Sclerosis (ALS), Traumatic Brain Injury (TBI), Multiple Sclerosis (MS), Clinical Depression, Alzheimer’s Disease, Blood Sepsis, Atherosclerosis, Anti-aging and Cancer. We have developed an aggressive timetable to advance the development of these breakthrough technologies. We have a management team with extensive experience and contacts in the medical/pharmaceutical fields as well as a demonstrated track record of launching new business ventures in a competitive environment. Our extensive contacts in the medical/pharmaceutical industries will ensure that new developments will achieve maximum visibility and exposure to the market..
Safe Harbor Notice
Certain statements contained herein are “forward-looking statements” (as defined in the Private Securities Litigation Reform Act of 1995). Premier Biomedical, Inc. cautions that statements, and assumptions made in this news release constitute forward-looking statements and makes no guarantee of future performance. Forward-looking statements are based on estimates and opinions of management at the time statements are made. These statements may address issues that involve significant risks, uncertainties, estimates made by management. Actual results could differ materially from current projections or implied results. Premier Biomedical, Inc. undertakes no obligation to revise these statements following the date of this news release.
About Uptick Newswire and the “Stock Day Podcast”
Uptick Newswire is a private company reaching out to the masses keeping investors and shareholders up to date on company news and bringing transparency to the undervalued, undersold, micro-cap stocks of the market and is the sole producer of the Uptick Network “Stock Day” Podcast. The Uptick Network “Stock Day” Podcast is an extension of Uptick Newswire and has recently launched the Video Interview Studio located in Phoenix, Arizona.
Source: Uptick Newswire
For further information please contact: William A. Hartman President and CEO Premier Biomedical Inc. (724) 633-7033 [email protected] www.premierbiomedical.com


Palantir Stock Soars as AI Demand Drives Strong Q2 Earnings and Higher 2026 Outlook
Novo Nordisk Eyes Turnaround as Oral Wegovy Challenges Eli Lilly in Weight-Loss Drug Race
DHL Q2 Profit Jumps 24% as Express Business Drives Growth
SK Hynix Bonus Dispute Deepens as Union Rejects Stock-Based Payout Proposal
Prysmian Nears Deal to Acquire Atkore in Potential All-Cash Takeover
Boeing Stock Jumps as FAA Certifies 737 MAX-7 After Years of Regulatory Review
Novo Nordisk Raises 2025 Outlook Despite Wegovy Pill Miss and CagriSema Setback
Heineken H1 Operating Profit Meets Forecast as Beer Volumes Beat Expectations
HSBC H1 Profit Jumps 23%, Announces $1 Billion Share Buyback and Reaffirms 2028 Targets
Jetstar to Charge for Overhead Cabin Bags From February
UK AI Security Tests Reveal Anthropic and OpenAI Agents Attempted Unauthorized Actions
Samsung, SK Hynix Test AMEC Chipmaking Tools for China Backup Plan
Alibaba Stock Jumps as Qwen 3.8-MAX AI Model Intensifies China's AI Race
FleetPartners Shares Jump After A$760 Million Takeover Proposal From Pacific Equity Partners
Meta Cuts Wipro Outsourcing by 25% After AI-Led Restructuring
Glencore Posts Strong H1 2026 Earnings, Announces ASX Secondary Listing
Bayer Q2 Earnings Beat Forecasts as Crop Science Boosts Results, Debt Outlook Improves 



